Research Library › Bioregulators & Thymic
Cardiogen is the name used for the synthetic tetrapeptide H-Ala-Glu-Asp-Arg-OH (AEDR). It is one of the short peptide bioregulators developed by Vladimir Khavinson’s group in St. Petersburg, Russia. A patent with a 22 Jun 2004 priority date, naming Khavinson and three co-inventors, claims the peptide as a heart-muscle-directed substance. As of 23 Oct 2026 it is not approved by the FDA, and it has not been nominated for FDA compounding review.
Key facts
| Type | Synthetic tetrapeptide (4 amino acids) |
|---|---|
| Sequence | H-Ala-Glu-Asp-Arg-OH (AEDR); C18H31N7O9; MW about 489.5 |
| First described | Patent priority 22 Jun 2004; U.S. Patent 7,662,789 granted 16 Feb 2010 |
| Developed by | Vladimir Khavinson, Galina Ryzhak, Evgeny Grigoriev, Irina Ryadnova; original assignee Access Bioscience CJSC |
| Institution | St. Petersburg Institute of Bioregulation and Gerontology |
| Designed target | Proposed by its developers as a heart-tissue (myocardium) peptide bioregulator |
| Regulatory status (Oct 2026) | Not FDA-approved; not on FDA's 503A, 503B or Category 2 lists |
Who developed it
Cardiogen belongs to the family of short peptide bioregulators created by Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology [4, 5]. U.S. Patent 7,662,789, titled “Peptide substance restoring myocardium function,” names Khavinson, Galina Ryzhak, Evgeny Grigoriev and Irina Ryadnova as inventors. It was originally assigned to Access Bioscience CJSC [1]. The patent claims the tetrapeptide alanyl-glutamyl-aspartyl-arginine [1].
The name Cardiogen appears in the Russian research literature by 2009 [3]. Khavinson’s 2012 laboratory paper on the same sequence refers to it simply as H-Ala-Glu-Asp-Arg-OH [2]. Research suppliers list Cardiogen and AEDR as the same compound [6].
What it was designed to target
Khavinson’s program grew out of earlier work with peptide extracts from animal organs, largely from cattle. His group called these tissue-specific regulatory peptides cytomedins, a concept set out by Morozov and Khavinson in the 1980s [4]. The program later turned to short synthetic di-, tri- and tetrapeptides intended to mirror particular organs. Cardiogen was the one assigned to heart tissue [1, 4].
The developers’ proposed mechanism is that short peptides enter cells and interact with DNA and histone proteins, influencing gene expression [4, 5]. AEDR is among the peptides they reported to bind histones H1, H2b, H3 and H4 in laboratory experiments [4]. A 2012 study measured expression of cytoskeletal proteins (actin, tubulin, vimentin) and nuclear-matrix proteins (lamins A and C) in cultured mouse embryonic fibroblasts exposed to the tetrapeptide [2]. These proposals come mainly from the developers’ own laboratories and have not been independently established.
Why it was created
Khavinson’s institute spent decades studying peptides as possible regulators of aging, a body of work its leaders summarized in 2009 as 35 years of research [5]. Within that framework, the program aimed to create a short synthetic peptide for each major organ system. Cardiogen was originally investigated in a research program on heart muscle, as reflected in its patent title [1].
Research timeline
- 1980s: Morozov and Khavinson describe tissue-specific regulatory peptides (cytomedins) [4].
- 22 Jun 2004: Priority date of the AEDR heart-peptide patent family [1].
- 2009: “Cardiogen peptide” studied in rat models in a paper in Bulletin of Experimental Biology and Medicine [3].
- 16 Feb 2010: U.S. Patent 7,662,789 granted [1].
- 2012: Khavinson and colleagues report gene-expression studies of H-Ala-Glu-Asp-Arg-OH in cultured fibroblasts [2].
Regulatory status as of October 2026
As of 23 Oct 2026, Cardiogen is not approved by the FDA, and no approved U.S. drug contains it. It does not appear on FDA’s list of bulk drug substances nominated for 503A compounding (updated 14 May 2026) [7]. It is also absent from the 503B nomination list [8] and the Category 2 list of substances that may present significant safety risks [9], and it was not on the 2026 agendas of FDA’s Pharmacy Compounding Advisory Committee [10]. Google Patents lists U.S. Patent 7,662,789 as expired for non-payment of fees [1].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What is Cardiogen?
Cardiogen is the name used for the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR). It is one of Vladimir Khavinson’s short peptide bioregulators and was assigned by its developers to heart tissue.
Who developed Cardiogen?
Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. The U.S. patent names Khavinson, G.A. Ryzhak, E.I. Grigoriev and I.Yu. Ryadnova as inventors.
What is Cardiogen's amino acid sequence?
H-Ala-Glu-Asp-Arg-OH: alanine, glutamic acid, aspartic acid and arginine. Its formula is C18H31N7O9.
Is Cardiogen FDA approved?
No. As of 23 Oct 2026 it is not FDA-approved and has not been nominated for FDA compounding review. It is sold only for laboratory research.
Sources
- Khavinson VK, Ryzhak GA, Grigoriev EI, Ryadnova IY. Peptide substance restoring myocardium function. US 7,662,789 B2 (priority 22 Jun 2004; granted 16 Feb 2010; original assignee Access Bioscience CJSC). Link
- Khavinson VK, Lin'kova NS, Polyakova VO, et al. Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins. Bull Exp Biol Med. 2012;153:559-562. doi:10.1007/s10517-012-1766-9 Link
- Levdik NV, Knyazkin IV. Tumor-modifying effect of Cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009;148:433-436. doi:10.1007/s10517-010-0730-9 Link
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053 Link
- Khavinson VK, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2009;148:94. doi:10.1007/s10517-009-0650-8 Link
- NovoPro Labs. Cardiogen/AEDR peptide: H-Ala-Glu-Asp-Arg-OH, C18H31N7O9, MW 489.47 (product listing). Link
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated 14 May 2026). Link
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the FD&C Act (updated 21 Mar 2025). Link
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 Apr 2026). Link
- Latham & Watkins. FDA on Peptides: A New Landscape for Compounders (2026), summarizing 91 Fed. Reg. 20465 (16 Apr 2026) and the PCAC meeting agendas. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
